Literature DB >> 7635052

Stem cell defects in parthenogenetic peri-implantation embryos.

E D Newman-Smith1, Z Werb.   

Abstract

Mouse embryos containing only maternal chromosomes (parthenotes) develop abnormally in vivo, usually failing at the peri-implantation stage. We have analyzed the development of parthenote embryos by using an inner cell mass (ICM) outgrowth assay that mimics peri-implantation development. ICMs from normal embryos maintained undifferentiated stem cells positive for stage-specific embryonic antigen-1 and Rex-1 while differentiating into a variety of cell types, including visceral endoderm-like cells and parietal endoderm cells. In contrast, ICMs from parthenotes failed to maintain undifferentiated stem cells and differentiated almost exclusively into parietal endoderm. This suggests that parthenote ICMs have a defect that leads to differentiation, rather than maintenance, of the stem cells, and a defect that leads to a parietal endoderm fate for the stem cells. To test the hypothesis that the ICM population is not maintained owing to a lack of proliferation of the stem cells, we investigated whether mitogenic agents were able to maintain the ICM population in parthenotes. When parthenote blastocysts were supplied with the insulin-like growth factor-1 receptor (Igf-1r) and insulin-like growth factor-2 (Igf-2), two genes not detectable in parthenote blastocysts by in situ hybridization, the ICM population was maintained. Similarly, culture of parthenote blastocysts in medium conditioned by embryonic fibroblasts and supplemented with the maternal factor leukemia inhibitory factor maintained the ICM population. However, once this growth factor-rich medium was removed, the parthenote ICM cells still differentiated predominantly into parietal endoderm.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635052     DOI: 10.1242/dev.121.7.2069

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  7 in total

1.  High-throughput screen for genes predominantly expressed in the ICM of mouse blastocysts by whole mount in situ hybridization.

Authors:  Toshiyuki Yoshikawa; Yulan Piao; Jinhui Zhong; Ryo Matoba; Mark G Carter; Yuxia Wang; Ilya Goldberg; Minoru S H Ko
Journal:  Gene Expr Patterns       Date:  2005-12-01       Impact factor: 1.224

Review 2.  Parthenotes as a source of embryonic stem cells.

Authors:  T A L Brevini; F Gandolfi
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

3.  In vivo and in vitro differentiation of uniparental embryonic stem cells into hematopoietic and neural cell types.

Authors:  Sigrid Eckardt; Timo C Dinger; Satoshi Kurosaka; N Adrian Leu; Albrecht M Müller; K John McLaughlin
Journal:  Organogenesis       Date:  2008-01       Impact factor: 2.500

4.  Germline competency of parthenogenetic embryonic stem cells from immature oocytes of adult mouse ovary.

Authors:  Zhong Liu; Zhe Hu; Xinghua Pan; Minshu Li; Taiwo A Togun; David Tuck; Mattia Pelizzola; Junjiu Huang; Xiaoying Ye; Yu Yin; Mengyuan Liu; Chao Li; Zhisheng Chen; Fang Wang; Lingjun Zhou; Lingyi Chen; David L Keefe; Lin Liu
Journal:  Hum Mol Genet       Date:  2011-01-14       Impact factor: 6.150

5.  Effects of fibroblast growth factor 2 and insulin-like growth factor II on the development of parthenogenetic mouse embryos in vitro.

Authors:  L I Penkov; E S Platonov; D A New
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Jul-Aug       Impact factor: 2.416

Review 6.  Parthenogenesis as an approach to pluripotency: advantages and limitations involved.

Authors:  Tiziana A L Brevini; Georgia Pennarossa; Stefania Antonini; Fulvio Gandolfi
Journal:  Stem Cell Rev       Date:  2008-06-12       Impact factor: 5.739

7.  Human fetal liver stromal cells that overexpress bFGF support growth and maintenance of human embryonic stem cells.

Authors:  Jiafei Xi; Yunfang Wang; Peng Zhang; Lijuan He; Xue Nan; Wen Yue; Xuetao Pei
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.